Key Details
Annual ROE
-99.12%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 15, 2021Recent annual earnings:
Mar 31, 2021Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 19, 2022Analyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with YMTX included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Yumanity Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Yumanity Therapeutics?
- What is the ticker symbol for Yumanity Therapeutics?
- Does Yumanity Therapeutics pay dividends?
- What sector is Yumanity Therapeutics in?
- What industry is Yumanity Therapeutics in?
- What country is Yumanity Therapeutics based in?
- When did Yumanity Therapeutics go public?
- Is Yumanity Therapeutics in the S&P 500?
- Is Yumanity Therapeutics in the NASDAQ 100?
- Is Yumanity Therapeutics in the Dow Jones?
- When was Yumanity Therapeutics's last earnings report?
- When does Yumanity Therapeutics report earnings?
What is the primary business of Yumanity Therapeutics?
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
What is the ticker symbol for Yumanity Therapeutics?
The ticker symbol for Yumanity Therapeutics is NASDAQ:YMTX
Does Yumanity Therapeutics pay dividends?
No, Yumanity Therapeutics does not pay dividends
What sector is Yumanity Therapeutics in?
Yumanity Therapeutics is in the Healthcare sector
What industry is Yumanity Therapeutics in?
Yumanity Therapeutics is in the Biotechnology industry
What country is Yumanity Therapeutics based in?
Yumanity Therapeutics is headquartered in United States
When did Yumanity Therapeutics go public?
Yumanity Therapeutics's initial public offering (IPO) was on 11 February 2016
Is Yumanity Therapeutics in the S&P 500?
No, Yumanity Therapeutics is not included in the S&P 500 index
Is Yumanity Therapeutics in the NASDAQ 100?
No, Yumanity Therapeutics is not included in the NASDAQ 100 index
Is Yumanity Therapeutics in the Dow Jones?
No, Yumanity Therapeutics is not included in the Dow Jones index
When was Yumanity Therapeutics's last earnings report?
Yumanity Therapeutics's most recent earnings report was on 15 November 2021
When does Yumanity Therapeutics report earnings?
The date for Yumanity Therapeutics's next earnings report has not been announced yet